Metformin in treatment of type 2 diabetes mellitus complicated with chronic kidney disease: Research advances / 国际药学研究杂志

ABSTRACT

Metformin is the preferred first-line drug by current global recommendation for the treatment of type 2 diabetes mellitus. Drug safety of patients with chronic kidney disease(CKD)has always been the focus of concern, so treatment of CKD by metformin has always been controversial. Recent studies at home and abroad have found that metformin’s treatment of CKD is safe, and the additional benefits far exceed the potential risks. The latest domestic and international guidelines also agree that CKD is not an absolute contraindication to metformin, and suggest relaxing the restriction of metformin for the treatment of mild and moderate renal insufficiency, but the use of metformin for medium and severe renal insufficiency remains controversial. The latest research data and guidelines about the safety of metformin’s treatment of CKD are reviewed in this article to provide a reference for clinical rational use of metformin.